TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

NSC 231634；TBB (enzyme inhibitor)；4,5,6,7-四溴-1H-苯并三唑

白色固体

Ethanol : 100 mM

DMSO : ≥430 mg/mL

CK2 ,CK1

In the presence of 10 μM TBB (and 100 μM ATP) only CK2 was drastically inhibited (s85%) whereas three kinases (phosphorylase kinase, glycogen synthase kinase 3L and cyclin-dependent kinase 2/cyclin A) underwent moderate inhibition, with IC50 values one-two orders of magnitude higher than CK2 (IC50 = 0.9 μM). TBB discriminates between CK2 and CK1, being much more e¡ective with the former.

The extent of retinal neovascularization in a mouse OIR model is reduced by approximately 60% after treatment with TBB (6 days at 60 mg/kg per day).

1. Orzechowska E, et al. Oncol Rep. 2012 Jan;27(1):281-5.

2. Nakanishi K, et al. Thromb Res. 2010 Dec;126(6):511-6.